Skip Navigation

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (3)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Yeoh, S.
Right arrow Articles by Siderov, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yeoh, S.
Right arrow Articles by Siderov, J.
Related Collections
Right arrow Rheumatoid Arthritis
Right arrow Education
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Rheumatology 2001; 40: 230-232
© 2001 British Society for Rheumatology

Letters to the Editor

Methotrexate misadventure: a case for counselling

S. Yeoh and J. Siderov1,

Pharmacist Intensive Care and Cardiothoracic Services and
1 Research and Cancer Services, Austin & Repatriation Medical Centre, Heidelberg 3084, Australia

The first 10% of the full text of this article appears below.

SIR, Methotrexate (MTX), a broad-spectrum anti-cancer agent, is used to treat a number of autoimmune diseases, including rheumatoid arthritis and psoriasis. Oral MTX carries particular risks of serious illness through inappropriate prescribing and dispensing errors. The majority of reported medication errors have been due either to the dispensing of the wrong strength, or the patient taking the wrong strength [1–4]. The risk of misadventure is increased when a patient has supplies of both strengths, as may be needed to provide a particular dose. Counselling patients receiving low-dose oral MTX is essential at each consultation and dispensing. We report . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?